CA1106285A - Procede d'obtention d'une fraction polaire naturelle a proprietes anti-psoriatiques - Google Patents

Procede d'obtention d'une fraction polaire naturelle a proprietes anti-psoriatiques

Info

Publication number: CA1106285A
Authority: CA; Canada
Prior art keywords: polypodium; rhyzomes; polar fraction; solution; evaporated
Prior art date: 1978-07-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA324,314A

Other languages

English (en)

Inventor

Francisco Ramon Alvarado Salgado

Blanca Zoila Ney Rivera

Antonio Horvath Sumi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CONRAD Ltd

Original Assignee

CONRAD Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-07-07

Filing date

1979-03-28

Publication date

1981-08-04

1979-03-28 Application filed by CONRAD Ltd filed Critical CONRAD Ltd

1981-08-04 Application granted granted Critical

1981-08-04 Publication of CA1106285A publication Critical patent/CA1106285A/fr

Status Expired legal-status Critical Current

Links

230000002682 anti-psoriatic effect Effects 0.000 title claims abstract description 6
238000000034 method Methods 0.000 title claims description 7
230000008569 process Effects 0.000 title claims 3
238000000605 extraction Methods 0.000 claims abstract description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 16
239000000243 solution Substances 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
239000008346 aqueous phase Substances 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
241000244324 Polypodium aureum Species 0.000 claims description 2
241000592274 Polypodium vulgare Species 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000002244 precipitate Substances 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
241000723185 Cyathea Species 0.000 claims 1
241000393483 Dryopteris crassirhizoma Species 0.000 claims 1
241001518143 Polypodium <fern> Species 0.000 claims 1
241001362840 Serpocaulon triseriale Species 0.000 claims 1
229940075984 polypodium leucotomos Drugs 0.000 claims 1
230000001376 precipitating effect Effects 0.000 claims 1
239000003643 water by type Substances 0.000 claims 1
241000985694 Polypodiopsida Species 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 9
201000004681 Psoriasis Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
241000196324 Embryophyta Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000006193 liquid solution Substances 0.000 description 3
239000006194 liquid suspension Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001185 psoriatic effect Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
238000011282 treatment Methods 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000001840 Dandruff Diseases 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241001310793 Podium Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
206010033898 parapsoriasis Diseases 0.000 description 2
230000008807 pathological lesion Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241001061225 Arcos Species 0.000 description 1
208000036487 Arthropathies Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
240000001879 Digitalis lutea Species 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001624848 Phlebodium Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000000059 bradycardiac effect Effects 0.000 description 1
230000002347 carcinogenetic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960001701 chloroform Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000727 fraction Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940124562 hematologic agent Drugs 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000003908 liver function Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000010827 pathological analysis Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000002345 steroid group Chemical group 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Natural Medicines & Medicinal Plants (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Alternative & Traditional Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Botany (AREA)
Medical Informatics (AREA)
Dermatology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA324,314A 1978-07-07 1979-03-28 Procede d'obtention d'une fraction polaire naturelle a proprietes anti-psoriatiques Expired CA1106285A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES471572A ES471572A1 (es)	1978-07-07	1978-07-07	Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica
ES471.572		1978-07-07

Publications (1)

Publication Number	Publication Date
CA1106285A true CA1106285A (fr)	1981-08-04

Family

ID=8476458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA324,314A Expired CA1106285A (fr)	1978-07-07	1979-03-28	Procede d'obtention d'une fraction polaire naturelle a proprietes anti-psoriatiques

Country Status (35)

Country	Link
JP (1)	JPS6026376B2 (fr)
AR (1)	AR230188A1 (fr)
AT (1)	AT371715B (fr)
AU (1)	AU4876479A (fr)
BE (1)	BE874483A (fr)
CA (1)	CA1106285A (fr)
CH (1)	CH642085A5 (fr)
CS (1)	CS215008B2 (fr)
DD (1)	DD144719A5 (fr)
DE (1)	DE2900887A1 (fr)
DK (1)	DK180379A (fr)
EG (1)	EG14496A (fr)
ES (1)	ES471572A1 (fr)
FI (1)	FI792128A7 (fr)
FR (1)	FR2434819A1 (fr)
GB (1)	GB2024622B (fr)
GR (1)	GR65334B (fr)
HU (1)	HU179689B (fr)
IE (1)	IE48526B1 (fr)
IL (1)	IL57721A (fr)
IS (1)	IS2495A7 (fr)
IT (1)	IT7919807A0 (fr)
LU (1)	LU81464A1 (fr)
MA (1)	MA18512A1 (fr)
MX (1)	MX5596E (fr)
NL (1)	NL7905251A (fr)
NO (1)	NO792260L (fr)
NZ (1)	NZ190933A (fr)
OA (1)	OA06288A (fr)
PH (1)	PH14338A (fr)
PL (1)	PL124244B1 (fr)
PT (1)	PT69067A (fr)
RO (1)	RO76833A (fr)
SE (1)	SE7903762L (fr)
ZA (1)	ZA793398B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES470204A1 (es) *	1978-05-24	1979-01-01	Conrad Ltd	Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica
ES8104315A1 (es) *	1980-04-02	1981-04-16	Conrad Ltd	Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae.
NO150880C (no) *	1981-06-01	1985-01-16	Borregaard Ind	Nye aza-krone-etere og anvendelse derav
WO1989005651A1 (fr) *	1987-12-23	1989-06-29	Psoricur Ltd.	Compositions therapeutiques anti-psoriasiques
EP0503208A1 (fr) *	1991-03-08	1992-09-16	Maracuyama International, S.A.	Procédé d'obtention d'un extrait naturel soluble dans l'eau de feuilles et/ou de rhizomes de différentes fougères possédant une activité immunologique
JPH0633820U (ja) *	1992-10-13	1994-05-06	マルヤス機械株式会社	ローラコンベア
DE69527742T2 (de) *	1994-05-06	2002-12-05	Especialidades Farmaceuticas Centrum, S.A.	Pharmazeutische Zusammensetzung enthaltend Farnextrakt(e) zur Behandlung von neurodegenerativen Krankheiten.
ES2068163B1 (es) *	1994-05-06	1995-09-01	Esp Farmaceuticas Centrum Sa	Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes.
ES2137900B1 (es) *	1998-06-02	2000-08-16	Helsint S A L	Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos.
WO1999006058A1 (fr) *	1997-07-30	1999-02-11	Helsint, S.A.L.	Fractions hydrosolubles de phlebodium decumanum et leur utilisation en tant que complement nutritionnel chez des patients souffrant du sida et de cancer
ES2124675B1 (es) *	1997-07-30	1999-10-01	Helsint S A L	"formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida".
FR2863163B1 (fr) *	2003-12-04	2006-02-24	Oreal	Composition, notamment cosmetique, comprenant des extraits de fougere et de nacre
FR2876032B1 (fr) *	2004-10-05	2008-10-31	Greentech Sa Sa	Utilisation d'extraits de fougeres dans des preparations cosmetiques ou dermatologiques
US20060246115A1 (en) *	2005-03-04	2006-11-02	Ricardo Rueda	Nutritional products for ameliorating symptoms of rheumatoid arthritis
USD554789S1 (en) *	2006-09-14	2007-11-06	Huo-Tu Huang	Table lamp
AT515350A1 (de) *	2014-02-10	2015-08-15	Christoph Dipl Ing Brandstätter	Verfahren zur Herstellung eines Konzentrats eines Holzschutzmittels, damit hergestelltes Konzentrat und Verfahren zur Behandlung von Holz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB256768A (en) *	1925-07-17	1926-08-19	Francesco Fumarola	Process for extraction of the active biological principles from the ether extract of male fern
US3395223A (en) *	1965-05-13	1968-07-30	Carter Wallace	Fern extract for treating gastric ulcers
FR2395266A1 (fr) *	1977-06-23	1979-01-19	Suffren Ste Parti Brevets	-lactone monomeres et leurs polymeres, sels et derives, utilisables notamment comme colorants, adjuvants de tannage et medicaments
JPS5464870A (en) *	1977-10-21	1979-05-25	Gte Laboratories Inc	Solid state microwave power supply for electrodeless light source

1978
- 1978-07-07 ES ES471572A patent/ES471572A1/es not_active Expired
- 1978-12-27 AR AR274971A patent/AR230188A1/es active
- 1978-12-28 GR GR57991A patent/GR65334B/el unknown
1979
- 1979-01-11 DE DE19792900887 patent/DE2900887A1/de not_active Withdrawn
- 1979-01-12 PT PT69067A patent/PT69067A/pt unknown
- 1979-01-29 FR FR7902226A patent/FR2434819A1/fr active Granted
- 1979-02-01 IT IT7919807A patent/IT7919807A0/it unknown
- 1979-02-27 BE BE193723A patent/BE874483A/fr not_active IP Right Cessation
- 1979-03-28 CA CA324,314A patent/CA1106285A/fr not_active Expired
- 1979-04-27 SE SE7903762A patent/SE7903762L/xx unknown
- 1979-05-02 DK DK180379A patent/DK180379A/da not_active Application Discontinuation
- 1979-05-22 CH CH477779A patent/CH642085A5/de not_active IP Right Cessation
- 1979-05-24 JP JP54064871A patent/JPS6026376B2/ja not_active Expired
- 1979-05-24 GB GB7918174A patent/GB2024622B/en not_active Expired
- 1979-05-29 MX MX798029U patent/MX5596E/es unknown
- 1979-07-04 IL IL57721A patent/IL57721A/xx unknown
- 1979-07-05 NL NL7905251A patent/NL7905251A/nl not_active Application Discontinuation
- 1979-07-05 FI FI792128A patent/FI792128A7/fi not_active Application Discontinuation
- 1979-07-05 IS IS2495A patent/IS2495A7/is unknown
- 1979-07-05 LU LU81464A patent/LU81464A1/fr unknown
- 1979-07-06 CS CS794777A patent/CS215008B2/cs unknown
- 1979-07-06 PL PL1979216905A patent/PL124244B1/pl unknown
- 1979-07-06 HU HU79CO371A patent/HU179689B/hu unknown
- 1979-07-06 ZA ZA793398A patent/ZA793398B/xx unknown
- 1979-07-06 AT AT0471479A patent/AT371715B/de not_active IP Right Cessation
- 1979-07-06 MA MA18709A patent/MA18512A1/fr unknown
- 1979-07-06 NO NO792260A patent/NO792260L/no unknown
- 1979-07-06 OA OA56841A patent/OA06288A/fr unknown
- 1979-07-06 NZ NZ190933A patent/NZ190933A/xx unknown
- 1979-07-07 EG EG415/79A patent/EG14496A/xx active
- 1979-07-07 RO RO7998089A patent/RO76833A/fr unknown
- 1979-07-09 DD DD79214207A patent/DD144719A5/de unknown
- 1979-07-09 PH PH22755A patent/PH14338A/en unknown
- 1979-07-09 AU AU48764/79A patent/AU4876479A/en not_active Abandoned
- 1979-08-08 IE IE1274/79A patent/IE48526B1/en unknown

Also Published As

Publication number	Publication date
SE7903762L (sv)	1980-01-08
FR2434819B1 (fr)	1982-07-09
AU4876479A (en)	1980-01-10
GB2024622A (en)	1980-01-16
MA18512A1 (fr)	1980-04-01
ZA793398B (en)	1981-07-29
IE791274L (en)	1980-01-07
PL124244B1 (en)	1983-01-31
CS215008B2 (en)	1982-06-25
GR65334B (en)	1980-08-14
DK180379A (da)	1980-01-08
HU179689B (en)	1982-11-29
IL57721A0 (en)	1979-11-30
GB2024622B (en)	1983-03-30
FR2434819A1 (fr)	1980-03-28
IE48526B1 (en)	1985-02-20
BE874483A (fr)	1979-06-18
AT371715B (de)	1983-07-25
IL57721A (en)	1983-07-31
OA06288A (fr)	1981-06-30
EG14496A (en)	1984-03-31
JPS6026376B2 (ja)	1985-06-24
NZ190933A (en)	1982-11-23
MX5596E (es)	1983-11-04
DE2900887A1 (de)	1980-01-24
ES471572A1 (es)	1979-01-16
JPS5511570A (en)	1980-01-26
IT7919807A0 (it)	1979-02-01
NO792260L (no)	1980-01-08
PT69067A (en)	1979-02-01
PH14338A (en)	1981-05-29
AR230188A1 (es)	1984-03-01
IS2495A7 (is)	1981-02-06
ATA471479A (de)	1982-12-15
FI792128A7 (fi)	1981-01-01
RO76833A (fr)	1981-05-30
PL216905A1 (fr)	1980-04-21
LU81464A1 (fr)	1980-04-21
CH642085A5 (de)	1984-03-30
NL7905251A (nl)	1980-01-09
DD144719A5 (de)	1980-11-05

Legal Events

Date	Code	Title	Description
1998-08-04	MKEX	Expiry

Publication	Publication Date	Title
CA1106285A (fr)	1981-08-04	Procede d'obtention d'une fraction polaire naturelle a proprietes anti-psoriatiques
JPH01157995A (ja)	1989-06-21	鎮痛−抗炎症活性を有するガングリオシドの内部エステル
CN1210289C (zh)	2005-07-13	两头尖提取物的制备工艺和用途
WO2008145064A1 (fr)	2008-12-04	Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci
CA1122589A (fr)	1982-04-27	Procede pour l'obtention de terpenes naturels, antipsoriasiques
CA1176173A (fr)	1984-10-16	Procede de preparation d'un medicament pour le traitement de l'arthrite et d'autres affections de l'appareil locomoteur
JPS5859921A (ja)	1983-04-09	アマチヤヅルサポニンを含有する抗癌剤
JPS62132829A (ja)	1987-06-16	肝炎の治療剤
CN110604761B (zh)	2021-11-16	一种桑花片及其制备工艺与在治疗心脑血管疾病中的应用
JPS627172B2 (fr)	1987-02-16
CN113599375A (zh)	2021-11-05	一种治疗口腔疾病的经口给药药物及用途
JPS632928A (ja)	1988-01-07	鎮痛剤
JP2541231B2 (ja)	1996-10-09	新規化合物および該化合物を有効成分とする血小板凝集抑制剤
Boada et al.	1984	Cardiac and extracardiac activity of an ethanolic extract of leaves of Isoplexis canariensis
RU2257208C1 (ru)	2005-07-27	Фармацевтическая композиция, обладающая гепатозащитным действием, и лекарственное средство
CA1073816A (fr)	1980-03-18	Medicaments a base de derives du cholesterol agissant sur les mecanismes bio-protecteurs
CN116813814A (zh)	2023-09-29	红花膳食纤维、提取方法及其在制备治疗功能性便秘药物方面的应用
JPH06227997A (ja)	1994-08-16	利尿剤
JPH0987190A (ja)	1997-03-31	腎機能障害改善剤
JPS59104318A (ja)	1984-06-16	アミノ安息香酸誘導体を有効成分とする抗血栓剤
WO2019154015A2 (fr)	2019-08-15	Composé contenant de l'argon, son procédé de préparation et son utilisation
JPH0158163B2 (fr)	1989-12-11
CS221523B2 (en)	1983-04-29	Method of making the derivative of the 1,4-dioxanaphtalene
JPH0223528B2 (fr)	1990-05-24
DD144048A5 (de)	1980-09-24	Verfahren zur gewinnung natuerlicher terpene mit antipsoriatischer wirksamkeit